Mirae Asset Global Investments Co., Ltd. Fibrogen Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$0.73 - $2.73 $40,742 - $152,364	55,811 New	55,811 $131,000
Q3 2023 Oct 26, 2023	SELL	$0.79 - $2.83 $39,774 - $142,482	-50,347 Reduced 82.83%	10,440 $8,000
Q2 2023 Aug 10, 2023	SELL	$2.49 - $20.59 $16,575 - $137,067	-6,657 Reduced 9.87%	60,787 $164,000
Q1 2023 May 04, 2023	BUY	$15.95 - $25.18 $235,150 - $371,228	14,743 Added 27.97%	67,444 $1.26 Million
Q4 2022 Feb 09, 2023	BUY	$13.27 - $17.73 $49,775 - $66,505	3,751 Added 7.66%	52,701 $844,000
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $96,774 - $123,939	8,489 Added 20.98%	48,950 $636,000
Q2 2022 Jul 26, 2022	BUY	$7.94 - $12.96 $233,563 - $381,231	29,416 Added 266.33%	40,461 $427,000
Q1 2022 May 10, 2022	SELL	$12.02 - $16.79 $8,606 - $12,021	-716 Reduced 6.09%	11,045 $133,000
Q4 2021 Feb 08, 2022	BUY	$9.93 - $15.39 $2,075 - $3,216	209 Added 1.81%	11,761 $166,000
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $13,569 - $35,511	1,333 Added 13.04%	11,552 $118,000
Q2 2021 Aug 11, 2021	BUY	$18.57 - $35.68 $189,766 - $364,613	10,219 New	10,219 $272,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.